HOME >> BIOLOGY >> NEWS
New analyses reinforce efficacy of Remicade in treatment of severe psoriasis

WASHINGTON, DC, February 2, 2007 -- Findings from an integrated analysis of data from three pivotal, randomized, placebo-controlled trials showed that at week 10 more than three-quarters of patients with severe psoriasis receiving REMICADE (infliximab) 3 mg/kg or 5 mg/kg achieved a 75 percent improvement in the chronic, inflammatory skin disease as measured by the Psoriasis Area Severity Index (PASI 75). In addition, in a separate analysis, investigators presented findings from a Phase 3 study, which showed that patients treated with REMICADE experienced significant and progressive improvements in psoriasis affecting the nails. Nail disease occurs in up to 50 percent of people with psoriasis. These findings were presented today at the 65th Annual Meeting of the American Academy of Dermatology.

"The integrated data show the substantial efficacy of REMICADE and present great hope for patients with severe psoriasis, particularly those patients burdened with this chronic disease who previously failed phototherapy or systemic therapy," said Alan Menter, MD, dermatologist, Baylor Research Institute, Dallas, and lead study investigator.

In the analysis of 1462 randomized patients, 991 patients (68 percent) met criteria for severe disease as defined by a body surface area (BSA) of at least 20 percent. Out of the 991 patients, 73 percent and 69 percent of study patients had received previous phototherapy or systemic therapy, respectively. At week 10, among patients with severe psoriasis treated with REMICADE (combined 3 mg/kg and 5 mg/kg groups), 79 percent of patients who had received prior phototherapy and 76 percent who had been previously treated with one or more systemic agents achieved PASI 75, compared with three percent and one percent, respectively, of placebo patients (P < 0.001, for both). In a separate analysis from the Evaluation of Infliximab for Psoriasis in a [REMICADE] Efficacy and Safety Study (EXPRESS II), among patients wit
'"/>

Contact: Brian Kenney
215-620-0111
Centocor, Inc.
2-Feb-2007


Page: 1 2 3 4 5 6

Related biology news :

1. A thesis of the UGR analyses more than 20-million-year-old vegetation to study climatic evolution
2. Cold Spring Harbor Protocols highlights reliable methods for gene and protein analyses
3. Genetic research at Childrens Hospital of Pittsburgh reinforces theory of evolution
4. 16-Year follow-up study reinforces Betaseron long-term efficacy, safety and tolerability in MS
5. New NIST reference material reinforces fragile-x screens
6. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
7. Enhanced MR-guided focused ultrasound guidelines demonstrate improved efficacy and durability
8. Enhancing chemotherapys efficacy: New agent has synergistic effect with standard drugs
9. Tumor response may not be best measure of efficacy in non-small cell lung cancer treatment
10. New 5 year Metvix-PDT data demonstrate long-term efficacy & reliability for NM skin cancer treatment
11. Pramipexole delivered sustained efficacy in clinical trial of patients with Restless Legs Syndrome

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/8/2019)... ROSKILDE, Denmark and RALEIGH, N.C. (PRWEB) , ... ... ... leader in micro acoustic and micro mechanical technologies and solutions for hearing instruments ... sensor technology, today announced BiometRIC, the first ever hearing aid receiver in canal ...
(Date:1/4/2019)... ... January 02, 2019 , ... Lifecycle Biotechnologies announces ... life science tools and service supplier turned 40 in 2018 and for the ... features not just part numbers like most catalogs, but rather, insightful information into ...
(Date:12/27/2018)... FRANCISCO (PRWEB) , ... December 27, 2018 , ... ... annual Microbiome Conference at JPM as part of the JP Morgan 37th Annual ... innovative scientists and physicians, and members of the investment community. , Since ...
Breaking Biology News(10 mins):
(Date:12/10/2018)... ... December 10, 2018 , ... ... Contract Development and Manufacturing Organization (CDMO) with sites in China and the ... manufacturing, and aseptic fill finish solutions for monoclonal antibody (mAb) and antibody-drug ...
(Date:12/5/2018)... ... ... The incredible life story of former refugee and LG Sonic CEO Yousef ... the European Commissioner for Research and Innovation. , In his November 27th speech ... spoke at length of Yousef’s life and journey, citing the man who convinced him ...
(Date:12/5/2018)... Va. and LONDON (PRWEB) , ... ... ... Research Group (ARG), an established North American full-service contract research organization (CRO), ... Effective immediately, the transaction significantly strengthens ARG’s reach and experience in the ...
(Date:11/28/2018)... ... November 28, 2018 , ... Earlier this month, Lajollacooks4u's ... as well as experience the height of truffle season. , Her first ... pristine countryside. Staying in the exclusive Black Truffle Lodge in the small mountain village ...
Breaking Biology Technology:
Cached News: